Literature DB >> 20876777

Natural killer cells and hepatitis C: action and reaction.

Kuldeep Cheent1, Salim I Khakoo.   

Abstract

In 1989, hepatitis C virus (HCV) was first identified as the infectious agent responsible for human non-A, non-B hepatitis. Two decades later, HCV remains a global public health problem with a suboptimal response rate to treatment and the absence of a protective vaccine. Recent work has highlighted the influence of the innate immune system, and in particular natural killer cells, on the outcome and pathology of HCV infection. These cells are considerably more complex than was originally thought and their role in viral infections is currently being unravelled. This review summarises our emerging understanding of natural killer cells in HCV infection.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20876777     DOI: 10.1136/gut.2010.212555

Source DB:  PubMed          Journal:  Gut        ISSN: 0017-5749            Impact factor:   23.059


  39 in total

1.  Natural killer cell activation enhances immune pathology and promotes chronic infection by limiting CD8+ T-cell immunity.

Authors:  Philipp A Lang; Karl S Lang; Haifeng C Xu; Melanie Grusdat; Ian A Parish; Mike Recher; Alisha R Elford; Salim Dhanji; Namir Shaabani; Charles W Tran; Dilan Dissanayake; Ramtin Rahbar; Magar Ghazarian; Anne Brüstle; Jason Fine; Peter Chen; Casey T Weaver; Christoph Klose; Andreas Diefenbach; Dieter Häussinger; James R Carlyle; Susan M Kaech; Tak W Mak; Pamela S Ohashi
Journal:  Proc Natl Acad Sci U S A       Date:  2011-12-13       Impact factor: 11.205

Review 2.  Understanding the role of killer cell immunoglobulin-like receptors in pregnancy complications.

Authors:  R Díaz-Peña; M J de Los Santos; Alejandro Lucia; P Castro-Santos
Journal:  J Assist Reprod Genet       Date:  2019-03-07       Impact factor: 3.412

3.  Non-neutralizing epitopes induce robust hepatitis C virus (HCV)-specific antibody-dependent CD56+ natural killer cell responses in chronic HCV-infected patients.

Authors:  L Long; M Jia; X Fan; H Liang; J Wang; L Zhu; Z Xie; T Shen
Journal:  Clin Exp Immunol       Date:  2017-04-07       Impact factor: 4.330

Review 4.  Tissue-specific effector functions of innate lymphoid cells.

Authors:  Niklas K Björkström; Eliisa Kekäläinen; Jenny Mjösberg
Journal:  Immunology       Date:  2013-08       Impact factor: 7.397

5.  Natural killer inhibitory receptor expression associated with treatment failure and interleukin-28B genotype in patients with chronic hepatitis C.

Authors:  Lucy Golden-Mason; Kiran M Bambha; Linling Cheng; Charles D Howell; Milton W Taylor; Paul J Clark; Nezam Afdhal; Hugo R Rosen
Journal:  Hepatology       Date:  2011-08-24       Impact factor: 17.425

6.  Peginterferon Alfa-2a/Ribavirin treatment efficacy in chronic hepatitis C patients is related to natural killer group 2D gene rs1049174 GC polymorphism.

Authors:  Abolghasem Asadi-Saghandi; Ali Shams; Gilda Eslami; Seyed Ali Mirghanizadeh; Ebrahim Eskandari-Nasab
Journal:  Virusdisease       Date:  2016-09-28

Review 7.  Hepatitis C virus in the new era: perspectives in epidemiology, prevention, diagnostics and predictors of response to therapy.

Authors:  Filippo Ansaldi; Andrea Orsi; Laura Sticchi; Bianca Bruzzone; Giancarlo Icardi
Journal:  World J Gastroenterol       Date:  2014-08-07       Impact factor: 5.742

Review 8.  Molecular pathways: hepatitis C virus, CXCL10, and the inflammatory road to liver cancer.

Authors:  Jessica Brownell; Stephen J Polyak
Journal:  Clin Cancer Res       Date:  2013-01-15       Impact factor: 12.531

Review 9.  Viral (hepatitis C virus, hepatitis B virus, HIV) persistence and immune homeostasis.

Authors:  Yun Zhou; Ying Zhang; Jonathan P Moorman; Zhi Q Yao; Zhan S Jia
Journal:  Immunology       Date:  2014-11       Impact factor: 7.397

Review 10.  Variable NK cell receptors and their MHC class I ligands in immunity, reproduction and human evolution.

Authors:  Peter Parham; Ashley Moffett
Journal:  Nat Rev Immunol       Date:  2013-01-21       Impact factor: 53.106

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.